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Cogan’s syndrome (CS) is a chronic inflammatory disorder of unknown etiology that most commonly affects young adults.
Clinical hallmarks are bilateral interstitial keratitis and vestibuloauditory dysfunction. Association between CS and systemic
vasculitis as well as aortitis also exists. The diagnosis of CS is based upon presence of characteristic inflammatory eye disease
and vestibuloauditory dysfunction. We describe classic Cogan’s syndrome in a 47-year-old female from Ardabil. The patient
was admitted with headache, vertigo, nausea, vomiting, right leg claudication, musculoskeletal pains, bilateral hearing loss, and
blindness for the past two months. Ophthalmologic examination revealed that visual acuity was 0.1 bilaterally. Conjunctival
hyperemia, bilateral cataract, and interstitial keratitis were detected with a slit lamp examination. Pure tone audiogram (PTA)
and auditory brain stem response (ABR) showed bilateral sensorineural hearing loss. The other differential diagnosis of CS was
studied and ruled out. Pulse i.v. methylprednisolone and cyclophosphamide were given and were followed by oral prednisolone
and cyclophosphamide. Clinical follow-up showed partial improvement.
1. Introduction
Cogan’s syndrome (CS) is a rare chronic inflammatory dis-
order characterized by nonsyphilitic interstitial keratitis and
vestibuloauditory dysfunction [1]. Associations between CS
and systemic vasculitis as well as aortitis also exist [2–4]. The
peak incidence of CS occurs in the third decade of life. In the
two largest series to date, themedian age of onset was 22 years
(range 5 to 63 years) [2, 3]. CS may also occur in children
and the elderly [5–7]. There is no known gender or racial
predominance. Fewer than five percent of patients initially
present with systemicmanifestations. In these cases, the diag-
nosis of CS can only be established after the development of
eye or inner ear disease [8]. The predominant ocular feature
of CS is interstitial keratitis (IK), which typically causes eye
redness, pain, photophobia, and blurred vision. On examina-
tion of patients with IK, an irregular, granular corneal infil-
tration is observed, affecting particularly the posterior part
of the cornea, near the limbus. Although IK is the classic eye
finding, it is not essential for the diagnosis. Ocular inflam-
mation may involve other parts of the eye and lead to
iridocyclitis, conjunctivitis, episcleritis, anterior or posterior
scleritis, or retinal vasculitis [3, 8–10]. The inner ear manifes-
tations of CS are Me´nie`re’s-like attacks consisting of vertigo,
ataxia, nausea, vomiting, tinnitus, and hearing loss [11]. Most
patients do not develop features of more widespread systemic
vasculitis, with the exception of aortitis and aneurysm or aor-
tic insufficiency, occurring in about 12% of patients [8]. A def-
inite diagnosis of CS is based upon characteristic involvement
of both the eye and inner ear, supported by the histologic
abnormalities and exclusion of other conditions.
We report a case of a typical Cogan’s syndrome, the
workup of the diagnosis, and treatment results.
2. Presentation Case
A 47-year-old female was hospitalized due to headache, ver-
tigo, nausea, vomiting, right leg claudication,musculoskeletal
Hindawi Publishing Corporation
Case Reports in Medicine
Volume 2014, Article ID 830831, 4 pages
http://dx.doi.org/10.1155/2014/830831
2 Case Reports in Medicine
Figure 1: Slit lamp examination of the eye showed interstitial
keratitis.
pains, progressive bilateral hearing loss, and blindness for the
past two months. At the time of admission, brachial blood
pressure was 125/75mmHg in the left arm and 120/70mmHg
in the right arm. The pulse rate was 85 beats per minute
and respiration rate was 18 breaths per minute. Her body
temperature was 37.1∘C. Heart and lung sounds were normal.
Ophthalmologic examination revealed that visual acuity was
0.1 bilaterally, and intraocular pressure was 15mmHg in both
eyes. On biomicroscopy, bilateral ciliary hyperemia, cataract,
and interstitial keratitis withmarginal infiltrates were noticed
(Figure 1). The fundus examination revealed mild hyperemia
of both optic discs, with blurred borders, andno signs of vitre-
ous or retinal inflammation. Pure tone audiogram (PTA) and
auditory brainstem responses (ABR) showed bilateral sen-
sorineural hearing loss (Figure 2).
The laboratory test results were as follows: white blood
cell count 10,200/mm3, hemoglobin 9.8 g/dL, platelet count
340,000/mm3, erythrocyte sedimentation rate 65mm/hr,
and C-reactive protein 13.1mg/dL. She tested negative for
autoimmune tests (anti-nuclear antibody, anti-neutrophil
cytoplasmic antibody rheumatoid factors, anti-phospholipid
antibodies, complements, and cryoglobulins) and negative
for syphilis serology tests (VDRL, FTA-Abs). Laboratory tests
and cerebrospinal fluid (CSF) analysis were all negative for an
infection (antibodies IgG and IgM against Epstein-Barr virus,
herpes zoster virus, herpes simplex virus, Cytomegalovirus,
chlamydia, hepatitis viruses B andC,HIV,Toxoplasma gondii,
andMycobacterium tuberculosis). The cerebral magnetic res-
onance imaging (MRI), computer tomography of the chest
and abdomen, colonoscopy, endoscopy, and biopsy of minor
salivary glands were all normal.
Based on audiovestibular and ocular findings and
given the excluding the infectious, neoplastic, granuloma-
tous, and autoimmune etiologies, the diagnosis of “typical”
Cogan’s syndrome was established. After the treatment with
intravenous methylprednisolone (1 gr/day for 5 days) and
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Figure 2: Audiogram showing bilateral moderate sensorineural
hearing loss.
cyclophosphamide (1 gr/month for 7 months) her general
condition stabilized, anterior eye segment changes improved,
and inflammatory parameters remained in normal range.
During the following six months, systemic prednisone was
gradually reduced to 30mg/d, cyclophosphamide was dis-
continued, and oral methotrexate 20mg/week was given.
However, clinical follow-up showed partial improvement.
3. Discussion
Cogan’s syndrome (CS) was first described in 1945 by an
ophthalmologist, Dr. Cogan, who reported on a syndrome of
nonsyphilitic interstitial keratitis (IK) and vestibuloauditory
symptoms that resembled Meniere’s disease [1]. In addition
to the ocular and audiovestibular involvement, numerous
systemic manifestations were reported in 1960 by Cody and
Williams in patients with CS [12]. More than 200 cases of
CS have been reported in the literature, despite being a rare
condition that mostly affects Caucasian young adults [11, 13].
In 1980, Haynes et al. [2] proposed diagnostic criteria for
typical and atypical CS, which include a large spectrum of
clinical manifestations. Typical CS is defined using Cogan’s
original criteria [1] with the following three conditions:
(1) ocular symptoms, nonsyphilitic IK; (2) audiovestibular
symptoms similar to those of Meniere’s syndrome (sudden
onset of tinnitus and vertigo, accompanied by gradual hear-
ing loss); and (3) an interval between the onset of ocular and
audiovestibularmanifestations of less than 2 years. According
to the criteria of Haynes et al. [2], patients with any of
the following symptoms are classified as having atypical CS:
(1) inflammatory ocular manifestations, with or without IK;
(2) typical ocular manifestations associated with audioves-
tibular symptoms different from Meniere’s-like episodes; or
(3) a delay of more than 2 years between the onset of typical
ocular and audiovestibular manifestations. In atypical CS,
where the ocular manifestation is episcleritis, scleritis, iritis,
uveitis, or chorioretinitis rather than interstitial keratitis,
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there is a worse prognosis and a higher frequency of aortic
and other systemic manifestations [11].
Recurrent episodes of inner ear disease frequently result
in profound hearing loss. In a retrospective series of 60
patients from one center, hearing loss was typically sudden,
bilateral, fluctuating, and progressive, resulting in complete
hearing loss in 73 of 120 ears [8]. Hearing loss in both ears
was noted at some point in all patients. Two smaller studies
both found bilateral deafness in approximately two-thirds of
patients [2, 3]. Typically, audiometry testing demonstrates a
sensorineural hearing loss, preferentially involving the low
and high range frequencies; poor speech discrimination is
also observed. In one preliminary study, at least 30 percent of
patients had a pure tone audiometry threshold of greater than
or equal to 60 dB, a threshold value indicative of moderately
severe hearing loss [4]. Hearing loss is often bilateral from
onset but in some patients it may be unilateral initially,
becoming bilateral later. In the review by Vollertsen et al. [3],
which included 78 patients with typical Cogan’s syndrome,
bilateral deafness affected 43.5% of patients and occurred a
mean of 3 months after the onset of the initial symptoms.
When present, the systemic vasculitis associated with CS
is a large- or medium- to small-sized vessel vasculitis, or an
aortitis. The pattern of vessel involvement may be overlap-
ping. Aortitis, which may develop within weeks to years of
disease onset, has been described in approximately 10 percent
of patients [2, 3, 11]. It may cause proximal aorta dilation, aor-
tic valvular regurgitation, ostial coronary artery disease, and
thoracoabdominal aortic aneurysms [11, 14–18]. A coronary
arteritis has also been described [3, 19, 20]. The large vessel
vasculitis associated with CS may also resemble Takayasu’s
arteritis, causing an occlusion of the aortic arch vessels with
resultant upper and/or lower limb claudication, or renal
artery stenosis [14, 19, 21, 22]. A small- or medium-sized
vessel arteritis has been described in some cases [23].
Nonspecific systemic manifestations of CS include fever,
fatigue, weight loss, lymphadenopathy, hepatomegaly, hepati-
tis, splenomegaly, pulmonary nodules, pericarditis, abdom-
inal pain, arthralgia, arthritis, myalgia, and urticaria [4, 8,
10, 11]. The disorder has also been described in patients with
inflammatory bowel disease [24, 25].The differential diagno-
sis of CS includes diverse conditions that cause similar eye
and inner ear manifestations (Table 1).
Therapeutic options for the treatment of CS include the
use of topical agents for limited ocular disease and immuno-
suppressive therapy for more extensive ocular disease, inner
ear involvement, and/or systemic vasculitis. Systemic corti-
costeroids are always the most widely used and successful
therapy in Cogan’s syndrome. For patients requiring high and
prolonged doses, additional immunosuppression is appro-
priate. Methotrexate is the first-line steroid sparing agent
[26, 27]. However, patients without systemic disease or severe
eye disease unmanageable by topical corticosteroids should
not be subjected to protracted courses of corticosteroids or
immunosuppressive agents, particularly when little gain in
hearing is obtained with their use [19]. The effect of TNF-
alpha blockers was recently investigated. Infliximab might be
an alternative therapy in cases of failure of corticosteroids and
immunosuppressive therapy [28, 29]. However, treatment
Table 1: Differential diagnosis of Cogan’s syndrome.
Sarcoidosis
Congenital syphilis
Whipple’s disease
Vogt-Koyanagi-Harada syndrome
KID (keratitis, ichthyosis, and deafness) syndrome
Sjo¨gren’s syndrome
Rheumatoid arthritis
Systemic lupus erythematosus
Granulomatosis with polyangiitis (Wegener’s)
Polyarteritis nodosa
Ulcerative colitis, Crohn’s disease
Central nervous system lymphoma/leukemia
Anti-phospholipid antibody syndrome
Behc¸et’s syndrome
Chlamydial infection
Viral infection
Herpes simplex and varicella zoster infection
Mycobacterium tuberculosis infection
Demyelinating disease (e.g., multiple sclerosis)
Cerebellopontine angle tumor
might be more effective when started at an early stage of the
disease, when the lesions are still reversible. Surgical bypass
grafting or aortic valve replacement may be required in some
patients [20].
4. Conclusion
Our case report of CS demonstrates objective, simultane-
ous deterioration of hearing and vestibular function, which
partially improved and stabilized after the introduction
of immunosuppressive medication. The diagnosis of CS is
largely based on clinical features, supported by the histologic
abnormalities and exclusion of other conditions. Treatment
might be more effective when started at an early stage of the
disease.
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